GSK plc vs iShares Core High Dividend ETF — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B). The key difference: GSK plc is far larger — about 6.3× iShares Core High Dividend ETF's market cap, and GSK plc pays a 3.9% dividend while iShares Core High Dividend ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and iShares Core High Dividend ETF for 117 Days on average.
| GSK | HDV | |
|---|---|---|
Market Cap | $91.88B | $14.68B |
Volume | 7,730,529 | 2,925,562 |
Sector | Health | — |
52-Week High | $61.18 | $29.93 |
52-Week Low | $43.24 | $23.64 |
Typical Hold Time | 93 Days | 117 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.36 exceeding the $1.27 estimate. Fundamentals show robust profitability with a 72.73% gross margin and 14.52% net margin, while valuation metrics like a P/E of 14.89 appear reasonable. Recent news highlights pipeline advancements, including a $750 million cancer therapy deal and strategic focus on oncology and cost savings.
The outlook is mixed; analyst consensus leans Hold (55.18%) with a minority Buy rating (31.03%), reflecting caution amid an approaching HIV patent cliff. Near-term support is at $45, with resistance at $47. Revenue growth to $33.2B in 2026 and a dividend of $0.45 per share offer stability, but execution risks and competitive pressures remain key watchpoints for investors.
HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% with strong bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities. Current dividend yield is approximately 3% with recent quarterly payouts between $0.06-$0.10 per share. Technical indicators show RSI at 77.74 suggesting potential overbought conditions near-term.
The outlook remains positive given the ETF's sector rotation toward defensive holdings and income focus, though concentration risk has increased with 62% in three sectors. Key risks include interest rate sensitivity and sector concentration, while opportunities lie in defensive positioning during market volatility. The 3% yield provides income appeal but requires monitoring of sector allocations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →